Biotech Strategy Blog

Commentary on Science, Innovation & New Products

ASCO 2014 What do oncologists think of PARP inhibitors?

PARP inhibitors have had a chequered history as anti-cancer agents from the lows of the failed iniparib (Sanofi) phase 3 trial in triple negative breast cancer (TNBC) and olaparib (AstraZeneca) in ovarian cancer to the highs of the initial waterfall plots for BMN673 (Biomarin) in BRCA-positive breast and ovarian cancers and a successful graduation from the ISPY2 trial in the triple negative signature for veliparib (AbbVie). In between those two extremes, there has been a lot of uncertainty.

Leave a comment

ASCO 2014 Annual Meeting Live Blog Day 4 #ASCO14

Chicago – it’s day 4 of the ASCO (American Society of Clinical Oncology) annual meeting. Sunday at ASCO can be a bit hit or miss depending on whether the plenary selection committee makes a good choice in which studies to give the “glory” and how interesting they are. It’s certainly been a busy meeting, although I have to say going round the poster halls has been a horrible experience. For the first time this year, they doubled up the trials in progress posters, which makes it like a rugby scrum to reach the QR code to get a copy, and all it means is that people use smaller text to cram the same material into a smaller area. People do want to talk people about what’s going on, the rational for trials and it must be a miserable experience for presenters to be faced with such cramped conditions. Memo to ASCO – it was not a good idea and the new poster numbering layout is really hard to follow. It’s not as if there is a shortage of space.

Leave a comment